Allegro and Senju in Japan eye disease deal
This article was originally published in Scrip
Executive Summary
Allegro Ophthalmics and Senju Pharmaceutical have signed a collaboration and license deal to develop integrin peptide therapy as a first-in-class treatment of vascular eye disease in Japan.